Professor John Radford, director of research at The Christie
At the start of the COVID-19 pandemic, our first concern at The Christie was keeping all of our patients safe. Because of this, we paused recruitment of new patients onto clinical trials.
Professor John Radford, director of research at The Christie, and the rest of his teams have been monitoring the situation closely. They’ve been looking at how they can work differently and what had to change, with patient and staff safety always their main focus.
And from 11 May, the research teams were able to start recruiting patients to certain clinical trials. Trials are not yet at full capacity as Professor Radford and the specialists need to keep a close watch on how things are progressing.
Not all trials have been reopened for recruitment yet and each trial will only take up to 5 patients initially. Once the first patients are on the trials, the research teams will review the situation based on current government guidance to work out the next steps.
In the video below, Professor Radford talks about how patient safety was the reason for pausing clinical trials initially. He also covers how he and the teams have been able to start opening some trials again and what this means for cancer patients.